Cormorant Asset Management’s Structure Therapeutics GPCR Stock Holding History

Cormorant Asset Management’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.03M	Sell	75,000 -100,000	-57%	-$4.42M	0.21%	42
2026 Q1	$8.44M	Buy	+175,000	New	+$12M	0.42%	39
2023 Q4	–	Sell	-1,056,373	Closed	-$53.3M	–	53
2023 Q3	$53.3M	Buy	1,056,373 +480,000	+83%	+$15.5M	3.11%	8
2023 Q2	$24M	Hold	576,373	–	–	1.34%	23
2023 Q1	$13.7M	Buy	+576,373	New	+$13.5M	0.9%	31

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jupiter Topco New York $245B AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Cormorant Asset Management's GPCR Position: Q2 2026 in Review

Cormorant Asset Management reduced its Structure Therapeutics (GPCR) stake by 57% in Q2 2026, selling an estimated $4.42M and leaving 75,000 shares worth $4.03M. The position accounts for 0.21% of the portfolio, ranked #42.

Cormorant Asset Management first reported a position in GPCR in Q1 2023 and has held it in 5 quarters since. The position peaked at $53.3M in Q3 2023. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

Cormorant Asset Management held 75,000 shares of Structure Therapeutics worth $4.03M as of Q2 2026.
Cormorant Asset Management sold 100,000 Structure Therapeutics shares in Q2 2026, an estimated $4.42M.
Structure Therapeutics made up 0.21% of Cormorant Asset Management's portfolio in Q2 2026, its #42 holding.
Cormorant Asset Management first reported a position in Structure Therapeutics in Q1 2023 and has held it in 5 quarters since.
Cormorant Asset Management's Structure Therapeutics position peaked at $53.3M in Q3 2023.
192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.